Roche acquired a portfolio of experimental cystic fibrosis therapies, including a candidate that has the potential to treat all patients with the disease.
Spero Therapeutics and the Bill & Melinda Gates Foundation teamed up to take on the challenge of a lung infection designated as a critical concern by the World Health Organization.
